VNA 932

Drug Profile

VNA 932

Alternative Names: WAY VNA 932

Latest Information Update: 27 Mar 2002

Price : $50

At a glance

  • Originator Wyeth
  • Class
  • Mechanism of Action Vasopressin V2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes insipidus; Urinary incontinence

Most Recent Events

  • 27 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
  • 21 Mar 2002 Discontinued - Preclinical for Urinary incontinence in USA (PO)
  • 21 Mar 2002 Discontinued - Phase-I for Diabetes insipidus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top